SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): October 24, 2003

                          CELLEGY PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
             (Exact name of Registrant as specified in its charter)

                                   California
             ------------------------------------------------------
                  (State or other jurisdiction of incorporation

         0-26372                                              82-0429727
----------------------------                          --------------------------
       (Commission                                          (IRS Employer
       File Number)                                      Identification No.)

                  349 Oyster Point Boulevard, Suite 200
                      South San Francisco, CA                       94080
--------------------------------------------------------------------------------
                (Address of principal executive offices)          (Zip Code)

                                 (650) 616-2200
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

--------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)


ITEM 5: OTHER EVENTS.

      On Friday,  Cellegy  Pharmaceuticals,  Inc. (the "Company") issued a press
release  regarding  the  initiation  by  PDI,  Inc.  of  non-binding   mediation
proceedings,  under the  December  31, 2002  exclusive  License  Agreement,  for
Cellegy's  Fortigel (TM) (testosteone  gel) product,  relating to certain claims
that PDI has made against  Cellegy.  A copy of that press release is attached as
an exhibit to this Report.

ITEM 7: FINANCIAL STATEMENTS AND EXHIBITS.

      (c)   Exhibits.

            99.1 Press Release dated October 24, 2003.


                                    SIGNATURE

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: October 27, 2003   CELLEGY PHARMACEUTICALS, INC.


                         By: /s/ A. Richard Juelis
                             ---------------------
                             A. Richard Juelis
                             Vice President, Finance and Chief Financial Officer


                                  EXHIBIT INDEX

Exhibit No.   Description
-----------   -----------

99.1          Press Release of Cellegy  Pharmaceuticals,  Inc. dated October 24,
              2003.